Indietro

Natera Inc

Ticker: NTRA ISIN: US6323071042
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap High beta Trading above 200-day average Near 52-week high
Capitalizzazione
20,91 Mld $
Forward P/E
0,00
Profit margin
-14,01%
Revenue growth QoQ
63,90%
Beta
1,65
332,03 $ 2,21%
Prezzo al 2026-08-21 · NASDAQ

Performance per periodo

Rendimenti cumulativi
1 Month +28,68%
6 Months +58,60%
1 Year +104,36%
5 Years +23,60% p.a.+188,30%
10 Years +42,22% p.a.+3.277,72%
Since inception +27,22% p.a.+1.360,11%
Rendimenti per anno
YTD +44,93%
2025 +44,72%
2024 +152,71%
2023 +55,94%
2022 -56,99%
2021 -6,16%

Key stats

Market cap
20,91 Mld
Beta
1,65
52-week range
75.19 - 183.00
50-day MA
168,08
200-day MA
132,74
Section 1

Business overview

Company profile data from fundamentals.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Sector Healthcare
Industry Diagnostics & Research
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -25,82%
ROA -9,96%
Profit margin -14,01%
Operating margin -8,94%
PEG ratio 0,00
Revenue/share TTM 12,59
Revenue TTM 1,53 Mld
EBITDA -214,40 Mln
Gross profit TTM 883,38 Mln
Beta 1,65

Valuation

Trailing P/E 0,00
Forward P/E 0,00
P/B 24,36
P/S 13,65
EV/EBITDA -26,80
EV/Revenue 13,68
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -1,55
Quarterly earnings growth 0,00%
Revenue TTM 1,53 Mld
Reported quarters 40
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 171,93 $
Analyst rating 4.5556

Ownership & short interest

Shares outstanding 132,02 Mln
Shares float 127,38 Mln
Institutional ownership 95,51%
Insider ownership 4,32%
Short ratio 3,23
Short % of float 3,54%

Details

Instrument metadata and source update timestamps.

Symbol NTRA
Name Natera Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US6323071042
Country USA
Code + exchange NTRA.NASDAQ
Fundamentals updated 2025-02-26

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.